Relationship between erythropoietin administration and alterations of renin-angiotensin-aldosterone

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 7, Issue 3, 2006, Pages 135-138

  Rosario, Reinaldo ^a,b   Epstein, Murray ^a,b,c  

^a DEPARTMENT OF COLORECTAL SURGERY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aldosterone; Chronic kidney disease; End stage renal disease; Erythropoletin; Renin angiotensin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; PLACEBO;

ANEMIA; CLINICAL TRIAL; DRUG RESPONSE; HUMAN; HYPERTENSION; KIDNEY FAILURE; PLASMA RENIN ACTIVITY; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN DISORDER; REVIEW; SYSTEMATIC REVIEW;

ERYTHROPOIETIN; HUMANS; KIDNEY FAILURE, CHRONIC; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 33751004121     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2006.022     Document Type: Review

References (25)

1. Eggena P, Willsey P, Jamgotchian N. Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Physiol 1991;261(5 PT 1):E642-6.
2. Brier M, Bunke M, Lathon P. Erythropoietin-induced antinatriuresis mediated by angiotensin II in perfused kidneys. J Am Soc Nephrol 1993;3:1583-90.
3. Nowicki M, Kokot F, Wiecek A. Influence of the renin-angiotensin system stimulation on erythropoietin production in patients with various forms of arterial hypertension. Nephron 1993;65:527-32.
4. Donnelly S, Miller J. Losartan may modulate erythropoietin production. JRAAS 2001;2:255-60.
5. Epstein M. Aldosterone as a mediator of progressive kidney disease: pathogenetic and clinical implications. Am J Kidney Dis 2004;37:677-88.
6. Epstein M. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J Hypertens 2001;19:829-42.
7. Lebel M, Kingma I, Grose JH et al. Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients. J Am Soc Nephrol 1998;9:97-104.
8. Portoles J, Torralbo A, Martin P et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997;29:541-8.
9. Arik N, Demirkan F, Erbas B. Acute effect of erythropoietin on plasma renin activity and aldosterone levels in end-stage renal disease. Nephron 1992;60:111.
10. Abraham PA, Opsahl JA, Rachael KM etal. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients. Am J Nephrol 1990;10:128-36.
11. Okura Y, Oshima T, Yasunobu Y et al. Effect of erythropoietin treatment on blood pressure and intracellular cation concentrations in maintenance hemodialysis patients. Hypertens Res Clin Exp 1996;19:91-5.
12. Vlahakos DV, Balodimos C, Papachristopoulos V et al. Renin-angiotensin system stimulates erythropoietin secretion in chronic hemodialysis patients. Clin Nephrol 1995;43:53-9.
13. Sasagawa I, Nakada T, Hashimoto T et al. Change in haemoglobin concentration, haematocrit and vasoactive hormones in haemodialysis patients with erythropoietin-associated hypertension. Int Urol Nephrol 1994;26:237-43.
14. Selcuk Y, San A, Sahin M et al. Effects of treatment with recombinant human erythropoietin on hemodynamic functions and vasoactive hormones in renal anemia. Tr J Med Sci 1994;22:271-5.
15. Yeksan M, Tamer N, Turk S et al. Hemodynamic changes with recombinant human erythropoietin therapy in uremic hemodialyzed patients. Tr J of Med Sci 1994;20:173-8.
16. Yaqoob M, Bell GM, Ahmad R et al. Suppression of the renin-angiotensin-aldosterone axis with erythropoietin therapy by a negative feedback loop. Nephrol Dial Transplant 1992;7:125-8.
17. Ono K, Hisasue Y. The rate in hematocrit, humoral vasoactive substances and blood pressure changes in hemodialysis patients treated with recombinant human erythropoietin or blood transfusion. Clin Nephrol 1992;37:23-7.
18. Jandeleit K, Ehmer B, Heintz B et al. Hormonal and electrolyte changes under regular therapy with recombinant human erythropoietin in hemodialysis patients. Contrib Nephrol 1991;91:57-60.
19. Kokot F, Wiecek A, Grzeszczak W et al. Influence of erythropoietin treatment on plasma renin activity, aldosterone, vasopressin and atrial natriuretic pepticle in haemodialyzed patients. Miner Electrolyte Metab 1990;16:25-9.
20. Hori K, Onoyama K, Iseki K et al. Hemodynamic and volume changes by recombinant human erythropoietin in the treatment of anemic hemodialysis patients. Clin Nephrol 1990;33:293-8.
21. Steffen HM, Brunner R, Müller R et al. Peripheral hemodynamics, blood viscosity, and the renin-angiotensin system in hemodialysis patients under therapy with recombinant human erythropoietin. Contrib Nephrol 1989;76:292-8.
22. Verbeelen D, Bossuyt A, Smitz J et al. Hemodynamics of patients with renal failure treated with recombinant human erythropoietin. Clin Nephrol 1989;13:6-11.
23. Epstein M. Aldosterone as a determinant of progressive renal dysfunction: a paradigm shift. NephSAP 2004;3:285-95.
24. Epstein M. Aldosterone receptor blockade and the role of eplerenone: evolving perspective. Nephrol Dial Transplant 2003;18:1984-92.
25. Silverberg D, Wexler D, Blum M et al. The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens 2004;13:163-70.